公开(公告)号：WO2007141626A1

公开(公告)日：2007-12-13

申请号：PCT/IB2007001483

申请日：2007-05-29

Applicant: PFIZER PROD INC ,  GUALBERTO ANTONIO ,  ROBERTS LUISA MARIA ,  MELVIN CARRIE LYNN ,  REPOLLET MADELINE I ,  CHIANESE DAVID ALLEN ,  CONNELY MARK CARLE ,  TERSTAPPEN LEONARDUS WENDELINU

Inventor： GUALBERTO ANTONIO ,  ROBERTS LUISA MARIA ,  MELVIN CARRIE LYNN ,  REPOLLET MADELINE I ,  CHIANESE DAVID ALLEN ,  CONNELY MARK CARLE ,  TERSTAPPEN LEONARDUS WENDELINU

IPC: G01N33/574 ,  G01N33/50

CPC classification number: G01N33/57496 ,  G01N30/02 ,  G01N33/5023 ,  G01N33/5064 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/4742 ,  G01N2333/4745 ,  G01N2333/71 ,  G01N2333/91205 ,  G01N2458/00 ,  G01N2800/52 ,  B01D15/3804

Abstract: Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.

Abstract translation: 公开了用于检测，计数和分析表达胰岛素样生长因子-1受体（IGF-1R）的循环肿瘤细胞的方法。 这些方法可用于癌症筛查和分期，治疗方案的开发以及用于监测治疗反应，癌症复发等的方法。 还提供了促进这种循环肿瘤细胞的检测，计数和分析的测试试剂盒。

公开(公告)号：WO2004084800A2

公开(公告)日：2004-10-07

申请号：PCT/US2003/027373

申请日：2003-08-29

Applicant: PFIZER PRODUCTS INC. ,  OXFORD GLYCOSCIENCES (UK) LTD. ,  THOMPSON, John, F. ,  POTTER, David, M. ,  KNIGHT, Delvin, R., Jr. ,  GUALBERTO, Antonio ,  LANDSCHULZ, Katherine, T. ,  HERATH, Herath, Mudiyanselage, Athula, Chandrasiri ,  ROHLFF, Christian

Inventor： THOMPSON, John, F. ,  POTTER, David, M. ,  KNIGHT, Delvin, R., Jr. ,  GUALBERTO, Antonio ,  LANDSCHULZ, Katherine, T. ,  HERATH, Herath, Mudiyanselage, Athula, Chandrasiri ,  ROHLFF, Christian

IPC: A61K

CPC classification number: C07K14/47 ,  A61K38/00 ,  G01N33/6893 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2500/20

Abstract: Proteins are identified that exhibit an altered expression in mammalian cardiac tissue in response to A 3 agonist infusion. These proteins are termed A 3 receptor-mediated cardioprotective proteins (A 3 Ps) and protein isoforms (A 3 PIs) and are useful as pharmaceuticals and as targets in screening methods for identifying an agent capable of modulating the expression of one or more A 3 P and/or A 3 PI.

Abstract translation: 鉴定出响应于A3激动剂输注在哺乳动物心脏组织中表现出改变的蛋白质。 这些蛋白质被称为A3受体介导的心脏保护性蛋白质（A3P）和蛋白质同种型（A3PI），并且可用作鉴定能够调节一种或多种A3P和/或A3PI的表达的试剂的筛选方法中的药物和靶标。

公开(公告)号：WO2022098953A1

公开(公告)日：2022-05-12

申请号：PCT/US2021/058185

申请日：2021-11-05

Applicant: EISAI R&D MANAGEMENT CO., LTD. ,  GUALBERTO, Antonio

Inventor： GUALBERTO, Antonio

IPC: A61K31/4439 ,  A61P35/00

Abstract: The present invention relates to methods of treating breast cancer patients with Compound 1 or pharmaceutically acceptable salts thereof. In some embodiments, the invention relates to treating patients meeting mutant allele frequency threshold values.

公开(公告)号：WO2022098712A1

公开(公告)日：2022-05-12

申请号：PCT/US2021/057839

申请日：2021-11-03

Applicant: EISAI R&D MANAGEMENT CO., LTD. ,  GUALBERTO, Antonio

Inventor： SCHOLZ, Catherine ,  XIAO, Jianjun Alan

IPC: A61K31/496 ,  A61P35/02 ,  A61P43/00

Abstract: The present disclosure relates to the treatment of transfusion dependence in myelodysplastic syndrome (MDS). The present disclosure relates to methods of using novel biomarkers to treat transfusion dependence in an MDS patient in need thereof. The present disclosure also relates to methods of identifying MDS patients suitable for treatment with a splicing modulator and/or predicting or monitoring treatment efficacy in an MDS patient. In some embodiments, the methods disclosed herein comprise determining at least the ratio of aberrant junction to canonical junction TMEM14C transcripts (TMEM14C AJ/CJ ratio) in the patient. In some embodiments, the methods disclosed herein comprise administering a therapeutically effective amount of a splicing modulator (e.g., Compound 1) based on the patient's TMEM14C AJ/CJ ratio. Therapeutic uses and compositions are also disclosed.

公开(公告)号：WO2006008639A8

公开(公告)日：2007-02-15

申请号：PCT/IB2005002096

申请日：2005-07-04

Applicant: PFIZER PROD INC ,  GUALBERTO ANTONIO ,  COHEN BRUCE DAVID ,  MELVIN CARRIE LYNN ,  ROBERTS MARIA LUISA

Inventor： GUALBERTO ANTONIO ,  COHEN BRUCE DAVID ,  MELVIN CARRIE LYNN ,  ROBERTS MARIA LUISA

IPC: A61K39/395

CPC classification number: A61K39/39541 ,  A61K31/28 ,  A61K31/337 ,  A61K31/573 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a therapeutic method for the treatment of non-hematologic malignancies comprising administering anti-IGF-1R antibodies, particularly human anti-IGF-1R antibodies, to a patient, in conjunction with the administration of at least one other therapeutic agent. The invention further relates to pharmaceutical compositions comprising these antibodies and methods of using such compositions thereof for treatment.

Abstract translation: 本发明涉及用于治疗非血液恶性肿瘤的治疗方法，其包括向患者施用抗IGF-1R抗体，特别是人抗IGF-1R抗体，连同施用至少一种其它治疗剂 。 本发明进一步涉及包含这些抗体的药物组合物及其组合物用于治疗的方法。

公开(公告)号：WO2011083391A3

公开(公告)日：2011-07-14

申请号：PCT/IB2010/056071

申请日：2010-12-24

Applicant: PFIZER INC. ,  GREEN, Stephanie Janet ,  GUALBERTO, Antonio

Inventor： GREEN, Stephanie Janet ,  GUALBERTO, Antonio

IPC: G01N33/74

Abstract: The present invention relates to use of free IGF-1 and the ratio of insulin/IGFBP in the blood as biomarkers for IGF-1 R antagonist therapy for cancer and to method for treating cancer with an IGF-1 R therapy in patients selected based on such biomarkers.

公开(公告)号：WO2007141626A8

公开(公告)日：2007-12-13

申请号：PCT/IB2007/001483

申请日：2007-05-29

Applicant: PFIZER PRODUCTS INC. ,  GUALBERTO, Antonio ,  ROBERTS, Luisa Maria ,  MELVIN, Carrie Lynn ,  REPOLLET, Madeline I. ,  CHIANESE, David Allen ,  CONNELLY, Mark, Carle ,  TERSTAPPEN, Leonardus, Wendelinus, Mathias, Marie

Inventor： GUALBERTO, Antonio ,  ROBERTS, Luisa Maria ,  MELVIN, Carrie Lynn ,  REPOLLET, Madeline I. ,  CHIANESE, David Allen ,  CONNELLY, Mark, Carle ,  TERSTAPPEN, Leonardus, Wendelinus, Mathias, Marie

IPC: G01N33/574 ,  G01N33/50

Abstract: Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.

公开(公告)号：WO2016081547A1

公开(公告)日：2016-05-26

申请号：PCT/US2015/061248

申请日：2015-11-18

Applicant: MERCK PATENT GMBH ,  THRESHOLD PHARMACEUTICALS, INC. ,  ELENBAAS, Brian A. ,  GUALBERTO, Antonio ,  HART, Charles Praray

Inventor： ELENBAAS, Brian A. ,  GUALBERTO, Antonio ,  HART, Charles Praray

IPC: A61K31/665 ,  A61K31/675 ,  A61K31/67 ,  C07F9/22 ,  A61P35/00

CPC classification number: A61K31/665 ,  A61K31/67 ,  A61K31/675 ,  C07F9/65062 ,  C07F9/65515 ,  C07F9/655345

Abstract: Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.

Abstract translation: 烯醇化酶水平预测癌症患者将有利地响应涉及施用缺氧激活的手性磷酰胺芥末的癌症治疗的可能性。

公开(公告)号：WO2006008639A1

公开(公告)日：2006-01-26

申请号：PCT/IB2005/002096

申请日：2005-07-04

Applicant: PFIZER PRODUCTS INC. ,  GUALBERTO, Antonio ,  COHEN, Bruce, David ,  MELVIN, Carrie, Lynn ,  ROBERTS, Maria, Luisa

Inventor： GUALBERTO, Antonio ,  COHEN, Bruce, David ,  MELVIN, Carrie, Lynn ,  ROBERTS, Maria, Luisa

IPC: A61K39/395

CPC classification number: A61K39/39541 ,  A61K31/28 ,  A61K31/337 ,  A61K31/573 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to a therapeutic method for the treatment of non-hematologic malignancies comprising administering anti-IGF-1R antibodies, particularly human anti-IGF-1R antibodies, to a patient, in conjunction with the administration of at least one other therapeutic agent. The invention further relates to pharmaceutical compositions comprising these antibodies and methods of using such compositions thereof for treatment.

Abstract translation: 本发明涉及用于治疗非血液恶性肿瘤的治疗方法，其包括向患者施用抗IGF-1R抗体，特别是人抗IGF-1R抗体，连同施用至少一种其它治疗剂 。 本发明进一步涉及包含这些抗体的药物组合物及其组合物用于治疗的方法。

公开(公告)号：WO2004084800A3

公开(公告)日：2005-10-06

申请号：PCT/US0327373

申请日：2003-08-29

Applicant: PFIZER PROD INC ,  OXFORD GLYCOSCIENCES UK LTD ,  THOMPSON JOHN F ,  POTTER DAVID M ,  KNIGHT DELVIN R JR ,  GUALBERTO ANTONIO ,  LANDSCHULZ KATHERINE T ,  HERATH HERATH MUDIYANSELAGE AT ,  ROHLFF CHRISTIAN

Inventor： THOMPSON JOHN F ,  POTTER DAVID M ,  KNIGHT DELVIN R JR ,  GUALBERTO ANTONIO ,  LANDSCHULZ KATHERINE T ,  HERATH HERATH MUDIYANSELAGE AT ,  ROHLFF CHRISTIAN

IPC: A61K20060101 ,  A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  G01N33/68

CPC classification number: C07K14/47 ,  A61K38/00 ,  G01N33/6893 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2500/20

Abstract: Proteins are identified that exhibit an altered expression in mammalian cardiac tissue in response to A3 agonist infusion. These proteins are termed A3 receptor-mediated cardioprotective proteins (A3Ps) and protein isoforms (A3PIs) and are useful as pharmaceuticals and as targets in screening methods for identifying an agent capable of modulating the expression of one or more A3P and/or A3PI.

Abstract translation: 鉴定出响应于A3激动剂输注在哺乳动物心脏组织中表现出改变的蛋白质。 这些蛋白质被称为A3受体介导的心脏保护性蛋白质（A3P）和蛋白质同种型（A3PI），并且可用作鉴定能够调节一种或多种A3P和/或A3PI的表达的试剂的筛选方法中的药物和靶标。